Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study (QUIéTUDE)

Study identification

• EU PAS number:
  EUPAS17989
• Study ID:
  19063
• Official title and acronym:
  Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study (QUIéTUDE)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  The aim of the study is to describe patient characteristics (demographic and clinical) and the patterns of use of Quetiapine XR in patients receiving the drug for the first time in real-life practice regardless the final diagnosis.
• Study status:
  Finalised

Research institutions and networks

Institutions

CHU de Clermont-Ferrand

Multiple centres: 275 centers are involved in the study

Study timelines

Date when funding contract was signed

Actual:14/11/2011

Study start date

Actual:11/12/2012

Data analysis start date

Actual:04/06/2014

Date of interim report, if expected

Actual:30/01/2015

Date of final study report

Actual:27/11/2015

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

NIS-NFR-SER-2012/1